Related Experiment Video
Updated: May 29, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Alternative pathways for angiotensin II generation in the cardiovascular system
C Becari1, E B Oliveira, M C O Salgado
1Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brasil. cbecari@usp.br
Summary
The renin-angiotensin system (RAS) generates Angiotensin II (Ang II) via ACE, but alternative pathways exist. Elastase-2 is identified as a key alternative enzyme for Ang II generation, impacting cardiovascular function.
Area of Science:
- Cardiovascular Physiology
- Enzymology
- Pharmacology
Background:
- The classical renin-angiotensin system (RAS) regulates blood pressure and fluid balance.
- Angiotensin II (Ang II) is a key peptide in the RAS, targeted by ACE inhibitors for hypertension and heart failure.
- Ang II levels are maintained despite ACE inhibition or deletion, suggesting alternative Ang II-generating pathways.
Purpose of the Study:
- To review the pharmacological aspects of the RAS.
- To highlight elastase-2 as an alternative pathway for Ang II generation.
- To discuss the role of elastase-2 in the cardiovascular system.
Main Methods:
- Characterization of serine protease elastase-2 for Ang II generation from Ang I in rats.
- Studies in cardiovascular tissues of normotensive and spontaneously hypertensive rats.
Main Results:
- Elastase-2 has been characterized as an alternative pathway for Ang II generation from Ang I.
- Elastase-2 plays a role in the cardiovascular system, including the heart and blood vessels.
Conclusions:
- Alternative pathways are crucial for maintaining Ang II levels.
- Elastase-2 represents a significant alternative pathway for Ang II generation.
- Understanding elastase-2's role offers new pharmacological insights into RAS regulation.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...